Tocris Bioscience™ Carfilzomib

Description

Potent irreversible proteasome inhibitor; active in vivo

Carfilzomib is a potent irreversible proteasome inhibitor. Preferentially inhibits the chymotrypsin-like β5 subunit of the constitutive 20S proteasome (IC50 = 5.2 nM) and the β5i subunit of the immunoproteasome 20Si (LMP7; IC50 = 14 nM) in vitro with minimal cross-reactivity to other proteases. Exhibits little or no effect on PGPH and T-L activities. Activates prosurvival autophagy and induces cell apoptosis. Acts synergistically with dexamethasone (Cat. No. 1126). Suppresses tumor growth in an in vivo xenograft model. Decreases bone resorption and enhances bone formation in non-tumor bearing mice.

Specifications

• Chemical Name or Material: (αS)-α-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1 S)-3-methyl-1-[[(2 R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
• CAS: 868540-17-4
• Quantity: 10 mg
• Target: Proteasome Inhibitors
• Molecular Formula: C₄₀H₅₇N₅O₇
• Purity: 0.98